aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2024. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company (“aVenture”) is an independent research platform providing information and analysis about startups.
Certain metrics provided by aVenture may seek to assess the risks and opportunities associated with a company, fund, or its representatives (collectively “research”). aVenture seeks to provide this information with objectivity and fairness, and with diligence about its accuracy. Nonetheless, aVenture cannot provide assurance as to the accuracy of the information provided by our research. We strongly advise those using the research platform to seek multiple, independent sources for your research when making financial decisions.
Any links provided to other websites are offered as a matter of convenience and are not intended to imply that aVenture or its authors endorse, sponsor, promote, and/or are affiliated with the owners of or participants in those sites.
The aVenture platform also provides investment listings offered by independent investment advisers in the United States. aVenture is neither a registered investment adviser nor an exempt reporting adviser under the Investment Advisers Act of 1940, and no statements made by aVenture are intended to imply any financial instruments are under the counsel or advice of aVenture or its representatives.
Funds offered on the platform are generally managed by a private investment adviser that, unless stated otherwise, claims exemption from SEC or state registration. Investment funds presented on the platform are only available to investors who meet the requirements of the offering, and solicitations are not made outside those listed jurisdictions.
Additionally, each investment offered on the platform has qualifications for eligibility, including some offered only to Qualified Clients and/or Accredited Investors. Certain funds may be available to non-Qualified or Accredited investors, but only those who become personally known and identifiable to aVenture Investment Company staff, who have had an opportunity to assess the financial capacity and suitability for such an investment, and discuss its risks. Funds, when offered, are only offered following a review of a Private Placement Memorandum (PPM), subscription agreement, and other disclosures.
Investments in startups, venture capital, angel investments, private equity, real estate, stocks, and similar asset classes all involve risks, including: the risk of a decline in the value of your investments, including potentially large declines (suddenly and/or for long periods of time), the potential for illiquidity where part or all of a withdrawal request may not be honored on the date requested (even when a feature of the fund). These risks are heightened during periods of market duress.
Diversification has the possibility of reducing the magnitude of declines (either caused by market/economic factors, or by factors related to the individual company), but does not guarantee these risks have been fully or partially alleviated. Most importantly, past results are not an assurance of future outcomes. While most of these risks are shared and similarly held by other investment asset classes, we recommend investors only consider venture capital investments as part of a broader, diversified portfolio of stocks, bonds, and immediately accessible cash reserves.
From Startups | TechCrunch
By Kyle Wiggers
March 25, 2024
Last year, Salesforce, the company best known for its cloud sales support software (and Slack), spearheaded a project called ProGen to design proteins using generative AI. A research moonshot, ProGen could — if brought to market — help uncover medical treatments more cost effectively than traditional methods, the researchers behind it claimed in a January 2023 blog post.
ProGen culminated in research published in the journal Nature Biotech showing that the AI could successfully create the 3D structures of artificial proteins. But, beyond the paper, the project didn’t amount to much at Salesforce or anywhere else — at least not in the commercial sense.
That is, until recently.
One of the researchers responsible for ProGen, Ali Madani, has launched a company, Profluent, that he hopes will bring similar protein-generating tech out of the lab and into the hands of pharmaceutical companies. In an interview with TechCrunch, Madani describes Profluent’s mission as “reversing the drug development paradigm,” starting with patient and therapeutic needs and working backwards to create “custom-fit” treatments solution.
“Many drugs — enzymes and antibodies, for example — consist of proteins,” Madani said. “So ultimately this is for patients who would receive an AI-designed protein as medicine.”
While at Salesforce’s research division, Madani found himself drawn to the parallels between natural language (e.g. English) and the “language” of proteins. Proteins — chains of bonded-together amino acids that the body uses for various purposes, from making hormones to repairing bone and muscle tissue — can be treated like words in a paragraph, Madani discovered. Fed into a generative AI model, data about proteins can be used to predict entirely new proteins with novel functions.
With Profluent, Madani and co-founder Alexander Meeske, an assistant professor of microbiology at the University of Washington, aim to take the concept a step further by applying it to gene editing.
“Many genetic diseases can’t be fixed by [proteins or enzymes] lifted directly from nature,” Madani said. “Furthermore, gene editing systems mixed and matched for new capabilities suffer from functional tradeoffs that significantly limit their reach. In contrast, Profluent can optimize multiple attributes simultaneously to achieve a custom-designed [gene] editor that’s a perfect fit for each patient.”
It’s not out of left field. Other companies and research groups have demonstrated viable ways in which generative AI can be used to predict proteins.
Nvidia in 2022 released a generative AI model, MegaMolBART, that was trained on a data set of millions of molecules to search for potential drug targets and forecast chemical reactions. Meta trained a model called ESM-2 on sequences of proteins, an approach the company claimed allowed it to predict sequences for more than 600 million proteins in just two weeks. And DeepMind, Google’s AI research lab, has a system called AlphaFold that predicts complete protein structures, achieving speed and accuracy far surpassing older, less complex algorithmic methods.
Profluent is training AI models on massive data sets — data sets with over 40 billion protein sequences — to create new as well as fine-tune existing gene-editing and protein-producing systems. Rather than develop treatments itself, the startup plans to collaborate with outside partners to yield “genetic medicines” with the most promising paths to approval.
Madani asserts this approach could dramatically cut down on the amount of time — and capital — typically required to develop a treatment. According to industry group PhRMA, it takes 10-15 years on average to develop one new medicine from initial discovery through regulatory approval. Recent estimates peg the cost of developing a new drug at between several hundred million to $2.8 billion, meanwhile.
“Many impactful medicines were in fact accidentally discovered, rather than intentionally designed,” Madani said. “[Profluent’s] capability offers humanity a chance to move from accidental discovery to intentional design of our most needed solutions in biology.”
Berkeley-based, 20-employee Profluent is backed by VC heavy hitters including Spark Capital (which led the company’s recent $35 million funding round), Insight Partners, Air Street Capital, AIX Ventures and Convergent Ventures. Google chief scientist Jeff Dean has also contributed, lending additional credence to the platform.
Profluent’s focus in the next few months will be upgrading its AI models, in part by expanding the training data sets, Madani says, and customer and partner acquisition. It’ll have to move aggressively; rivals, including EvolutionaryScale and Basecamp Research, are fast training their own protein-generating models and raising vast sums of VC cash.
“We’ve developed our initial platform and shown scientific breakthroughs in gene editing,” Madani said. “Now is the time to scale and start enabling solutions with partners that match our ambitions for the future.”
View original article on techcrunch.com
Share:
Xaira, an AI drug discovery startup, launches with a massive $1B, says it’s ‘ready’ to start developing drugs
Advances in generative AI have taken the tech world by storm. Biotech investors are making a big bet that similar computational methods could revolutionize drug discovery. On Tuesday, ARCH Venture Partners and Foresite Labs, an affiliate of Foresite Capital, announced that they incubated Xaira Therapeutics and funded the AI biotech with $1 billion. Other investors […] © 2024 TechCrunch. All rights reserved. For personal use only.
Apr 25, 2024
Eric Schmidt-backed Augment, a GitHub Copilot rival, launches out of stealth with $252M
AI is supercharging coding — and developers are embracing it. In a recent StackOverflow poll, 44% of software engineers said that they use AI tools as part of their development processes now and 26% plan to soon. Gartner estimates that over half of organizations are currently piloting or have already deployed AI-driven coding assistants, and […] © 2024 TechCrunch. All rights reserved. For personal use only.
Apr 24, 2024
Radical thinks the time has come for solar-powered, high-altitude autonomous aircraft
Though many eyes are on space as orbit develops into a thriving business ecosystem, Radical is keeping things a little closer to the ground — but not too close. Its high-altitude, solar-powered aircraft aim to succeed where Facebook’s infamous Aquila failed by refining the tech and embracing more markets. It’s hard to believe that Facebook’s […] © 2024 TechCrunch. All rights reserved. For personal use only.
Apr 24, 2024
Don't miss our latest news and updates. Subscribe to the newsletter
More from Tech Crunch: